Results 231 to 240 of about 1,282,511 (265)

Case Report: Rapid response to gemtuzumab-ozogamicin in a pediatric patient with refractory systemic mastocytosis with AML1::ETO+ acute myeloid leukemia. [PDF]

Front Immunol
Xue S, Chen M, Sun HP, Wang T, Zhang LN, Cao XY.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

The international consensus classification of eosinophilic disorders and systemic mastocytosis

American journal of hematology/oncology, 2023
Based on new data and increased understanding of disease molecular genetics, the international consensus classification (ICC) has made several changes in the diagnosis and classification of eosinophilic disorders and systemic mastocytosis.
Sa A. Wang, A. Orazi, J. Gotlib, A. Reiter, A. Tzankov, R. Hasserjian, D. Arber, A. Tefferi   +7 more
semanticscholar   +1 more source

Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.

British Journal of Dermatology, 2023
BACKGROUND Indolent systemic mastocytosis (ISM) is characterized by excessive mast cell accumulation and mast cell-driven signs and symptoms. Currently used therapies are not approved and have limited efficacy.
F. Siebenhaar, S. Altrichter, H. Bonnekoh, T. Hawro, M. Hawro, E. Michaelis, A. Kantor, Alan T. Chang, Bradford A. Youngblood, Bhupinder B. Singh, H. Rasmussen, M. Maurer   +11 more
semanticscholar   +1 more source

Systemic mastocytosis: 2023 update on diagnosis and management in adults

Expert Opinion on Emerging Drugs, 2023
Introduction Systemic mastocytosis (SM) is a complex and heterogeneous disease, characterized by the clonal accumulation of mast cells in one or more organs. In 2022 both the World Health Organization (WHO) and the International Consensus Classification (
A. Costa, E. Scalzulli, I. Carmosino, M. Capriata, C. Ielo, Chiara Masucci, M. Passucci, M. Martelli, M. Breccia   +8 more
semanticscholar   +1 more source